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Prostate cancer is a significant public health problem.
In the European Union, approximately 200,000 men
are diagnosed annually and the incidence is increasing,
even allowing for the rise in screen-detected prostate
cancer. Multiple aetiologies have been proposed to
contribute to the development of prostate cancer.
However, there is strong evidence that inherited genetic
factors are important and contribute to significant familial
aggregation in some men, particularly when affected at
a young age (Woolf et al., 1960; Steinberg et al., 2000;
Singh, 2000; Edwards et al., 2003). The breast cancer
predisposition genes BRCA2, and possibly also BRCA1,
have been reported to increase the risk of prostate cancer
in male carriers of these genes; however, the prostate
cancer risk associated with carriage of BRCA gene
mutations remains uncertain. 
IMPACT (Identification of Men with a genetic
Predisposition to ProstAte Cancer: Targeted screening
in BRCA1 and BRCA2 mutation carriers and controls)
is the first multinational study to investigate screening
and diagnosis for men with a genetic risk of prostate
cancer. An international collaboration which currently
involves over 20 countries, the study aims to identify
and recruit 850 male BRCA1/BRCA2 mutation carriers,
and an equal number of controls (men with a negative
predictive BRCA1/2 genetic test), into a targeted
screening programme for prostate cancer. 
IMPACT aims to determine the sensitivity and specificity
of PSA screening for prostate cancer in BRCA1/2 carriers
and controls, and to evaluate new screening markers for
this disease. It also aims to gain a better understanding
of the pathogenicity of prostate cancer in men with BRCA1
or BRCA2 mutations, and will attempt to identify new
modifier genes or biomarkers for this population.
BRCA1 and BRCA2 are the only genes, thus far, with
an established role in increasing prostate cancer risk,
but it has been suggested that a number of other genes
exist which may predispose to prostate cancer (each
accounting for a proportion of familial prostate cancer
clusters). With the establishment of a solid IMPACT
consortium, it is hoped this study could be extended to
investigate other prostate cancer predisposition genes
if and when they are identified. 
Cancer research has been targeted as a high
priority for the European Community (EC); however,
research is most successful when centralised and well
co-ordinated, avoiding the duplication and
fragmentation associated with smaller, isolated studies.
The EC Framework 6 Programme, which aims to
facilitate co-operation between European countries in
the field of cancer research, has therefore provided
funding for IMPACT to be expanded to include clinical
and research teams in Bulgaria, Romania and Turkey
(and other Associated Candidate Countries and New
Member States of the EU). A subteam of IMPACT,
known as AIDIT (Advancing International Co-operation
and Developing Infrastructure for Targeted Screening
of Prostate Cancer in Men with Genetic Predisposition),
will focus on linking researchers in these new countries
with the established international IMPACT Consortium. 
The EC’s support of AIDIT provides the opportunity
for teams who might be new to research in genetics or
oncology to become integrated into an existing study.
Communication between new and existing collaborators
will allow the sharing of knowledge and formulation of
strategies to overcome local barriers and challenges.
The AIDIT team is in the process of establishing
a website to facilitate communication between current
and potential project collaborators. It will also fund and
facilitate an international conference to bring together
research teams, clinicians and policy makers from
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of familial prostate cancer among health professionals
and the public within Associated Candidate Countries
and New Member States of the EU.
Clinical and research teams who are interested in
participating in IMPACT or who would like to attend
the funded conference in Poland from 28 to 30
November are encouraged to contact the AIDIT
administrator (email: impact-study@icr.ac.uk or
telephone +44 (0) 208 661 3897).
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